Trastuzumab Deruxtecan

Phase 2Completed

2 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Conditions

Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Trial Timeline

Aug 20, 2021 → Feb 28, 2024

NCT ID

NCT04989816

About Trastuzumab Deruxtecan

Trastuzumab Deruxtecan is a phase 2 stage product being developed by Daiichi Sankyo for Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04989816. Target conditions include Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

What happened to similar drugs?

5 of 20 similar drugs in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma were approved

Approved (5) Terminated (3) Active (13)

✅ApatinibTabletsJiangsu Hengrui MedicineApproved

✅ApatinibJiangsu Hengrui MedicineApproved

✅Esomeprazole SodiumAstraZenecaApproved

✅trastuzumab [Herceptin]RocheApproved

✅Methylnaltrexone only + Codeine only + Methylnaltrexone + codeine + Placebo + placeboPfizerApproved

🔄Trastuzumab + Fluorouracil + Cisplatin + CapecitabineChugai PharmaceuticalPhase 3

🔄Trastuzumab deruxtecan + Ramucirumab + PaclitaxelDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (19)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07015697	Phase 1	Recruiting	Jul 17, 2025	Dec 31, 2028	Recurrent or Metastatic Solid Tumors
NCT06750484	Phase 2	Recruiting	Jun 20, 2025	Dec 31, 2028	Breast Cancer Metastatic
NCT05982678	Phase 2	Recruiting	May 2, 2024	Oct 1, 2034	HER2-positive Breast Cancer
NCT06386263	Pre-clinical	Completed	Apr 22, 2024	Jul 7, 2025	Unresectable Breast Cancer
NCT06210776	Pre-clinical	Recruiting	Jan 15, 2024	Mar 1, 2028	HER2-positive Breast Cancer
NCT05950945	Phase 3	Recruiting	Dec 30, 2023	Oct 1, 2027	Breast Cancer
NCT05993234	Pre-clinical	Recruiting	Dec 5, 2023	Sep 1, 2027	HER2-positive Advanced Gastric Cancer
NCT05945732	Pre-clinical	Recruiting	Oct 24, 2023	Sep 1, 2028	Unresectable Breast Cancer
NCT05458401	Pre-clinical	Completed	Nov 11, 2022	Dec 1, 2023	HER2-positive Breast Cancer
NCT05246514	Phase 2	Active	Jul 13, 2022	Mar 16, 2026	HER2-mutant Non-Small Cell Lung Cancer
NCT04989816	Phase 2	Completed	Aug 20, 2021	Feb 28, 2024	Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
NCT04739761	Phase 3	Active	Jun 22, 2021	May 26, 2026	Breast Cancer
NCT04644237	Phase 2	Completed	Mar 19, 2021	Aug 23, 2024	Non-Small Cell Lung Cancer
NCT04639219	Phase 2	Active	Dec 30, 2020	Jul 14, 2026	Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
NCT04482309	Phase 2	Recruiting	Aug 18, 2020	Jul 30, 2027	Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer
NCT04752059	Phase 2	Completed	Jul 28, 2020	May 1, 2023	Breast Cancer Stage IV
NCT04420598	Phase 2	Completed	May 25, 2020	Apr 4, 2023	Advanced Breast Cancer
NCT04014075	Phase 2	Completed	Nov 26, 2019	Feb 13, 2024	Adenocarcinoma Gastric Stage IV With Metastases
NCT03505710	Phase 2	Terminated	May 21, 2018	Apr 17, 2024	Non-Small Cell Lung Cancer

Competing Products

20 competing products in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

See all competitors

Product	Company	Stage	Hype Score
pemetrexed + cisplatin	Eli Lilly	Phase 1/2	32
Infigratinib	LianBio	Phase 2	17
Infigratinib	LianBio	Phase 2	21
Ramucirumab + MEDI4736	Eli Lilly	Phase 1	29
Ramucirumab	Eli Lilly	Phase 2	35
Trastuzumab + Capecitabine + Cisplatin	Celltrion	Phase 2	31
Trastuzumab + Fluorouracil + Cisplatin + Capecitabine	Chugai Pharmaceutical	Phase 3	40
Fluorouracil (5-FU) + Capecitabine + Durvalumab + Oxaliplatin + Trastuzumab + Trastuzumab deruxtecan + Cisplatin + Pembrolizumab + Volrustomig + Rilvegostomig	Daiichi Sankyo	Phase 2	42
Trastuzumab deruxtecan + Ramucirumab + Paclitaxel	Daiichi Sankyo	Phase 3	44
Trastuzumab deruxtecan	Daiichi Sankyo	Pre-clinical	33
Trastuzumab Deruxtecan (T-DXd) monotherapy + T-DXd, Durvalumab and Capecitabine Combination	Daiichi Sankyo	Phase 2	42
Trastuzumab deruxtecan + Bevacizumab	Daiichi Sankyo	Phase 2	42
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	35
Trastuzumab deruxtecan (T-DXd)	Daiichi Sankyo	Pre-clinical	33
DS-8201a	Daiichi Sankyo	Phase 1	29
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	39
Irinotecan + Nimotuzumab	Daiichi Sankyo	Phase 3	32
Trastuzumab Deruxtecan + pembrolizumab + Trastuzumab + Chemotherapy	Daiichi Sankyo	Phase 3	47
Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLO	Daiichi Sankyo	Phase 1/2	39
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	42